#Singapore #Emerald Clinical #Glenn Kerkhof #Mary Gunn

Emerald Clinical Trials Announces Leadership Change

Emerald Clinical Trials, a globally recognized clinical research organization, has made headlines with the announcement of a leadership transition. Mary Gunn has stepped down from her position as CEO, a decision that will usher in a new chapter for the company. In her place, Glenn Kerkhof, a seasoned professional with extensive experience in the clinical research field, has been appointed as interim CEO.

The board of directors has initiated a search for a permanent replacement while entrusting Kerkhof with the task of guiding the company during this transitional phase. The board expressed confidence in Kerkhof's ability to ensure continuity, stability, and a robust operational performance. Sean Carney, the chairman of the board, noted, “We thank Mary for her contributions. Emerald Clinical Trials is a leading contract research organization with a global footprint. With Glenn as interim CEO, we are confident that we can maintain our momentum and continue to deliver exceptional service to our clients.”

Glenn Kerkhof’s impressive resume boasts over 30 years of leadership experience in the clinical research arena, specifically within pharmaceutical services. His previous roles include CEO of Chiltern, where he successfully led the organization through substantial international expansion. Additionally, he served as Executive Chairman at George Clinical, now known as Emerald Clinical Trials, shaping the company’s growth in Asia.

In his first statements as interim CEO, Kerkhof remarked on the strengths of Emerald Clinical Trials, which lie in its therapeutic focus, scientific depth, and strong client partnerships. “I am focusing on ensuring a smooth transition, delivering strong performance for our clients, and supporting our global teams. I am determined to build upon our momentum and lead with clarity and purpose,” he stated.

Emerald Clinical Trials has established itself as a leading organization in clinical research, catering to over 100 biotechnology firms and six of the top ten pharmaceutical companies. Headquartered in Singapore, the firm offers comprehensive clinical trial services to clients across the globe, providing solutions for all phases of studies. For more information on their services and capabilities, visit www.emeraldclinical.com.

As the search for a permanent CEO continues, the commitment of the organization to its clients and to advancing clinical research remains steadfast. The leadership transition at Emerald Clinical Trials is poised to be a pivotal moment, creating opportunities for growth and innovation as they continue to navigate the complex landscape of clinical trials.